oneill74_JEFF PACHOUDAFP via Getty Images_coronavirusscientistlabtest Jeff Pachoud/AFP via Getty Images

The G20’s Pandemic Moment

Just as a meager investment to address antimicrobial resistance could yield a 2,000% return in the future, so, too, would an immediate modest outlay to finance development of COVID-19 therapeutics. As world leaders gather to formulate a response to the crisis, they must not lose sight of this simple cost-benefit calculus.

LONDON – This week, G20 leaders will convene virtually to discuss the COVID-19 crisis. One hopes that the emergency summit marks the beginning of a thoughtful collective response to this grave challenge. If so, the meeting may turn out to be even more consequential than the London summit hosted by British Prime Minister Gordon Brown in April 2009, which created the framework for a coordinated multilateral response to the global financial crisis.